Cargando…
Longer Hydroxyurea Administration Prior to Imatinib Mesylate is Risk Factor for Unsuccessful Major Molecular Response in Chronic-Phase Chronic Myeloid Leukemia: Possibility of P-Glycoprotein Role
OBJECTIVE: This study aimed to identify the association between duration of HU administration prior to IM treatment and MMR achievement in chronic-phase CML while evaluating the role of MDA, HIF-1α and P-gp. METHODS: The study was conducted at Dr. Cipto Mangunkusumo National General Hospital and Dha...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
West Asia Organization for Cancer Prevention
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7173389/ https://www.ncbi.nlm.nih.gov/pubmed/31870110 http://dx.doi.org/10.31557/APJCP.2019.20.12.3689 |
_version_ | 1783524441559400448 |
---|---|
author | Rinaldi, Ikhwan Reksodiputro, Ary Harryanto Jusman, Sri Widia Harahap, Alida Setiabudy, Rianto Wanandi, Septelia Inawati Tambunan, Karmel Suharti, Catharina |
author_facet | Rinaldi, Ikhwan Reksodiputro, Ary Harryanto Jusman, Sri Widia Harahap, Alida Setiabudy, Rianto Wanandi, Septelia Inawati Tambunan, Karmel Suharti, Catharina |
author_sort | Rinaldi, Ikhwan |
collection | PubMed |
description | OBJECTIVE: This study aimed to identify the association between duration of HU administration prior to IM treatment and MMR achievement in chronic-phase CML while evaluating the role of MDA, HIF-1α and P-gp. METHODS: The study was conducted at Dr. Cipto Mangunkusumo National General Hospital and Dharmais Cancer Hospital, Jakarta using retrospective cohort design to analyse the association between the duration of HU before IM and its MMR achievement and cross-sectional design to analyse the association between MDA, HIF-1α and P-gp expressions with MMR achievement. Main subjects were chronic-phase CML patients treated by HU prior to IM for ≥ 12 months and HU only. The subjects were divided into four main groups: (1) chronic-phase CML patients treated with HU ≤ 6 months + IM ≥ 12 months and (2) HU > 6 months + IM ≥ 12 months (3) HU only (≤ 6 months), (4) HU only ( >6 months). Subjects were obtained from January 2015 to May 2016. Data were gathered through history taking, physical examination, medical record evaluation, and blood sample analysis. Bivariate analysis was conducted using chi square, independent T-test, and Mann-Whitney according to the variables. RESULTS: Administration of HU for more than 6 months prior to IM was associated with unsuccessful MMR achievement (RR 1.60; 95%CI 1.29-2.00). MDA level, HIF-1α, P-glycoprotein expression were not associated with MMR achievement but the mean MDA level (0.63±0.31 vs 0.75±0.41 p=0.461) and median P-glycoprotein expressions {16,92 (0,04 – 43,86) vs. 5,15 (0,02–39,64); p=0.311} were found to be higher in patients receiving HU for > 6 months group than in HU ≤ 6 months group consecutively. CONCLUSION: Administration of HU for more than 6 months prior to IM was associated with unsuccessful MMR achievement in chronic-phase CML. The study suggested that P-glycoprotein overexpression as the predictor for unsuccessful MMR achievement. |
format | Online Article Text |
id | pubmed-7173389 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | West Asia Organization for Cancer Prevention |
record_format | MEDLINE/PubMed |
spelling | pubmed-71733892020-05-01 Longer Hydroxyurea Administration Prior to Imatinib Mesylate is Risk Factor for Unsuccessful Major Molecular Response in Chronic-Phase Chronic Myeloid Leukemia: Possibility of P-Glycoprotein Role Rinaldi, Ikhwan Reksodiputro, Ary Harryanto Jusman, Sri Widia Harahap, Alida Setiabudy, Rianto Wanandi, Septelia Inawati Tambunan, Karmel Suharti, Catharina Asian Pac J Cancer Prev Research Article OBJECTIVE: This study aimed to identify the association between duration of HU administration prior to IM treatment and MMR achievement in chronic-phase CML while evaluating the role of MDA, HIF-1α and P-gp. METHODS: The study was conducted at Dr. Cipto Mangunkusumo National General Hospital and Dharmais Cancer Hospital, Jakarta using retrospective cohort design to analyse the association between the duration of HU before IM and its MMR achievement and cross-sectional design to analyse the association between MDA, HIF-1α and P-gp expressions with MMR achievement. Main subjects were chronic-phase CML patients treated by HU prior to IM for ≥ 12 months and HU only. The subjects were divided into four main groups: (1) chronic-phase CML patients treated with HU ≤ 6 months + IM ≥ 12 months and (2) HU > 6 months + IM ≥ 12 months (3) HU only (≤ 6 months), (4) HU only ( >6 months). Subjects were obtained from January 2015 to May 2016. Data were gathered through history taking, physical examination, medical record evaluation, and blood sample analysis. Bivariate analysis was conducted using chi square, independent T-test, and Mann-Whitney according to the variables. RESULTS: Administration of HU for more than 6 months prior to IM was associated with unsuccessful MMR achievement (RR 1.60; 95%CI 1.29-2.00). MDA level, HIF-1α, P-glycoprotein expression were not associated with MMR achievement but the mean MDA level (0.63±0.31 vs 0.75±0.41 p=0.461) and median P-glycoprotein expressions {16,92 (0,04 – 43,86) vs. 5,15 (0,02–39,64); p=0.311} were found to be higher in patients receiving HU for > 6 months group than in HU ≤ 6 months group consecutively. CONCLUSION: Administration of HU for more than 6 months prior to IM was associated with unsuccessful MMR achievement in chronic-phase CML. The study suggested that P-glycoprotein overexpression as the predictor for unsuccessful MMR achievement. West Asia Organization for Cancer Prevention 2019 /pmc/articles/PMC7173389/ /pubmed/31870110 http://dx.doi.org/10.31557/APJCP.2019.20.12.3689 Text en This is an Open Access article distributed under the terms of the Creative Commons Attribution License, (http://creativecommons.org/licenses/by/3.0/) which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Research Article Rinaldi, Ikhwan Reksodiputro, Ary Harryanto Jusman, Sri Widia Harahap, Alida Setiabudy, Rianto Wanandi, Septelia Inawati Tambunan, Karmel Suharti, Catharina Longer Hydroxyurea Administration Prior to Imatinib Mesylate is Risk Factor for Unsuccessful Major Molecular Response in Chronic-Phase Chronic Myeloid Leukemia: Possibility of P-Glycoprotein Role |
title | Longer Hydroxyurea Administration Prior to Imatinib Mesylate is Risk Factor for Unsuccessful Major Molecular Response in Chronic-Phase Chronic Myeloid Leukemia: Possibility of P-Glycoprotein Role |
title_full | Longer Hydroxyurea Administration Prior to Imatinib Mesylate is Risk Factor for Unsuccessful Major Molecular Response in Chronic-Phase Chronic Myeloid Leukemia: Possibility of P-Glycoprotein Role |
title_fullStr | Longer Hydroxyurea Administration Prior to Imatinib Mesylate is Risk Factor for Unsuccessful Major Molecular Response in Chronic-Phase Chronic Myeloid Leukemia: Possibility of P-Glycoprotein Role |
title_full_unstemmed | Longer Hydroxyurea Administration Prior to Imatinib Mesylate is Risk Factor for Unsuccessful Major Molecular Response in Chronic-Phase Chronic Myeloid Leukemia: Possibility of P-Glycoprotein Role |
title_short | Longer Hydroxyurea Administration Prior to Imatinib Mesylate is Risk Factor for Unsuccessful Major Molecular Response in Chronic-Phase Chronic Myeloid Leukemia: Possibility of P-Glycoprotein Role |
title_sort | longer hydroxyurea administration prior to imatinib mesylate is risk factor for unsuccessful major molecular response in chronic-phase chronic myeloid leukemia: possibility of p-glycoprotein role |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7173389/ https://www.ncbi.nlm.nih.gov/pubmed/31870110 http://dx.doi.org/10.31557/APJCP.2019.20.12.3689 |
work_keys_str_mv | AT rinaldiikhwan longerhydroxyureaadministrationpriortoimatinibmesylateisriskfactorforunsuccessfulmajormolecularresponseinchronicphasechronicmyeloidleukemiapossibilityofpglycoproteinrole AT reksodiputroaryharryanto longerhydroxyureaadministrationpriortoimatinibmesylateisriskfactorforunsuccessfulmajormolecularresponseinchronicphasechronicmyeloidleukemiapossibilityofpglycoproteinrole AT jusmansriwidia longerhydroxyureaadministrationpriortoimatinibmesylateisriskfactorforunsuccessfulmajormolecularresponseinchronicphasechronicmyeloidleukemiapossibilityofpglycoproteinrole AT harahapalida longerhydroxyureaadministrationpriortoimatinibmesylateisriskfactorforunsuccessfulmajormolecularresponseinchronicphasechronicmyeloidleukemiapossibilityofpglycoproteinrole AT setiabudyrianto longerhydroxyureaadministrationpriortoimatinibmesylateisriskfactorforunsuccessfulmajormolecularresponseinchronicphasechronicmyeloidleukemiapossibilityofpglycoproteinrole AT wanandisepteliainawati longerhydroxyureaadministrationpriortoimatinibmesylateisriskfactorforunsuccessfulmajormolecularresponseinchronicphasechronicmyeloidleukemiapossibilityofpglycoproteinrole AT tambunankarmel longerhydroxyureaadministrationpriortoimatinibmesylateisriskfactorforunsuccessfulmajormolecularresponseinchronicphasechronicmyeloidleukemiapossibilityofpglycoproteinrole AT suharticatharina longerhydroxyureaadministrationpriortoimatinibmesylateisriskfactorforunsuccessfulmajormolecularresponseinchronicphasechronicmyeloidleukemiapossibilityofpglycoproteinrole |